United Imaging Healthcare
Chinese medical imaging manufacturer founded in 2011. Aggressive full-stack entrant — builds CT, MRI, PET/CT, SPECT, PET/MR, digital radiography, and proton therapy in-house. Disruptive pricing against the Big Three (GE / Siemens / Philips) in China + emerging markets; growing footprint in North America and Europe.
Company history
- 2011 — founded by former Siemens imaging executives in Shanghai.
- 2015 — ships first-generation uMR 1.5 T MRI, uCT, uMI PET/CT.
- 2018 — uEXPLORER prototype — first total-body PET/CT (194 cm axial FOV, vs ~25 cm on conventional premium PET/CT). Massive sensitivity gain for research + oncology.
- 2019 — FDA clearances for uMI, uCT, uMR family.
- 2020 — first US uEXPLORER install (UC Davis).
- 2022 — IPO on Shanghai STAR Market, valued ~$10 billion.
Product line
- CT — uCT family (uCT 960+, uCT 960, uCT ATLAS)
- MRI — uMR family (uMR Jupiter 5 T, uMR Ultra 3 T, uMR 1.5 T)
- PET/CT — uMI family (uMI 780, uMI Panorama GS digital) and uEXPLORER (total-body PET/CT)
- PET/MR — uPMR 790
- SPECT — uSPECT 980
- Digital radiography — uDR series
- Proton therapy — uRT linac + proton offerings
Distinctive tech
- uEXPLORER — total-body PET/CT with 194 cm axial FOV. ~40× sensitivity of conventional PET/CT. Enables novel protocols: ultra-low-dose imaging, dynamic whole-body kinetic modeling, pediatric scans with minimal dose.
- 5 T MRI (uMR Jupiter) — pushing clinical field strength beyond the 3 T commercial ceiling.
- Integrated full-stack strategy — unified software across modalities (uAI, uMI Intelligence Platform).
Market position
Dominant in China (state-level procurement). Growing rapidly in Southeast Asia, Middle East, Africa, Latin America. North American + European presence ramping through 2020s.